China Resources Double-Crane Pharmaceutical Co Ltd banner
C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 17.82 CNY -0.39% Market Closed
Market Cap: ¥18.5B

China Resources Double-Crane Pharmaceutical Co Ltd
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Resources Double-Crane Pharmaceutical Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Free Cash Flow
¥869.9m
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
5%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Free Cash Flow
¥4.5B
CAGR 3-Years
22%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Free Cash Flow
¥8.5B
CAGR 3-Years
N/A
CAGR 5-Years
46%
CAGR 10-Years
16%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Free Cash Flow
¥4.1B
CAGR 3-Years
14%
CAGR 5-Years
4%
CAGR 10-Years
7%
Zhejiang Nhu Co Ltd
SZSE:002001
Free Cash Flow
¥6.9B
CAGR 3-Years
N/A
CAGR 5-Years
55%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Free Cash Flow
¥4B
CAGR 3-Years
N/A
CAGR 5-Years
256%
CAGR 10-Years
N/A
No Stocks Found

China Resources Double-Crane Pharmaceutical Co Ltd
Glance View

Market Cap
18.5B CNY
Industry
Pharmaceuticals

In the dynamic landscape of China's pharmaceutical industry, China Resources Double-Crane Pharmaceutical Co Ltd emerges as a key player. It traces its roots back to the early 20th century, embodying a rich history of transformation and innovation. The company seamlessly integrates research, development, production, and sales, making it a formidable force in the healthcare sector. Primarily, it focuses on the production of chemical and biological drugs, catering to a wide range of therapeutic areas such as cardiovascular diseases, anti-infection solutions, and nutritional drugs. Through its comprehensive network, the company not only retains a robust domestic presence but also pushes its products into international markets, driving its revenue growth. Double-Crane's business model thrives on a blend of strategic partnerships and a strong emphasis on R&D. By collaborating with top research institutes and leveraging cutting-edge technology, it innovates new products to meet the rising demands of modern healthcare. The company’s substantial investment in R&D has allowed it to build a strong pipeline of proprietary drugs, ensuring a steady stream of products to boost its market position. With a keen eye on market trends and patient needs, China Resources Double-Crane continually optimizes its production processes and expands its distribution channels. This methodical approach enables the company to enhance its profitability while propelling it as a leader in the pharmaceutical industry.

Intrinsic Value
27.78 CNY
Undervaluation 36%
Intrinsic Value
Price ¥17.82
C

See Also

What is China Resources Double-Crane Pharmaceutical Co Ltd's Free Cash Flow?
Free Cash Flow
869.9m CNY

Based on the financial report for Dec 31, 2025, China Resources Double-Crane Pharmaceutical Co Ltd's Free Cash Flow amounts to 869.9m CNY.

What is China Resources Double-Crane Pharmaceutical Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
5%

Over the last year, the Free Cash Flow growth was -27%. The average annual Free Cash Flow growth rates for China Resources Double-Crane Pharmaceutical Co Ltd have been -1% over the past three years , -3% over the past five years , and 5% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett